Related Experiment Video

Updated: Jun 13, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

[Cardiogenic shock complicating acute myocardial infarction: trends in management and outcome]

Marco Grazi1, Stefania Farina, Emilio Assanelli

  • 1Centro Cardiologico Monzino, I.R.C.C.S., Dipartimento di Scienze Cardiovascolari, Università di Milano. marco.grazi@ccfm.it

Recenti Progressi in Medicina
|May 14, 2010
PubMed

Insights

Cardiogenic shock from acute myocardial infarction has high mortality despite advanced devices like intra-aortic balloon pumps. Further research is crucial for new treatments to improve survival rates in these critical patients.

Area of Science:

  • Cardiology
  • Critical Care Medicine

Background:

  • Cardiogenic shock complicating acute myocardial infarction (AMI) remains a critical condition with high mortality.
  • Despite advancements in medical stabilization and mechanical circulatory support, survival rates are still suboptimal.

Purpose of the Study:

  • To review the current survival rates in patients with cardiogenic shock post-AMI.
  • To highlight the limitations of existing therapies and underscore the need for novel therapeutic strategies.

Main Methods:

  • Review of current medical literature and clinical data on cardiogenic shock complicating AMI.
  • Analysis of survival outcomes in patients treated with intra-aortic balloon pump (IABP) and ventricular assist devices (VADs).

Main Results:

  • While IABP and VADs have improved survival, mortality rates for cardiogenic shock post-AMI remain high, approximately 30-40%.
  • Existing interventions are insufficient to overcome the severity of the condition in a significant proportion of patients.

Conclusions:

  • Current therapeutic strategies, including mechanical support, are inadequate to achieve substantial reductions in mortality for cardiogenic shock post-AMI.
  • Future research must prioritize the development and investigation of innovative treatment modalities to further decrease mortality in this high-risk patient population.

More Related Videos

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...